Yazar "Gurel, Selim" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort
    (Kare Publ, 2023) Yaras, Serkan; Demir, Mehmet; Barutcu, Sezgin; Yildirim, Abdullah Emre; Gurel, Selim; Ucbilek, Enver; Kurtulmus, Ilkce Akgun
    Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.
  • [ N/A ]
    Öğe
    Somatostatin Receptor 1 (SSTR1) and Somatostatin Receptor 5 (SSTR5) Expressions in Hepatocellular Carcinoma
    (H G E Update Medical Publishing S A, 2013) Koc, Ebru U.; Ozgur, Tumay; Yerci, Omer; Gurel, Selim
    Background/Aims: Somatostatin analogues are considered for the treatment of advanced hepatocellular carcinomas which express somatostatin receptors (SSTR). There is limited data for the SSTR subtypes. Somatostatin receptor 1 (SSTR1) and Somatostatin receptor 5 (SSTR5) expressions are investigated in needle biopsy materials of patients diagnosed as hepatocellular carcinoma, using immunohistochemical methods in the assistance of antibody kits. Methodology: The needle biopsy materials of forty-one patients that were diagnosed as hepatocellular carcinoma between 2000 and 2006 have been examined. The underlying diseases, AFP values, treatments received and the stages-of the subjects were taken under record. Biopsy sections were evaluated after SSTR1 and SSTR5 staining. Results: SSTR1 expression was found in 31 (75.6%) and SSTR5 expression in 21 of (51.2%) 41 biopsies. SSTR1 and SSTR5 expressions were not determined in 10 (24.4%) and 20 (48.8%) of the cases. In addition, no significant correlation of the SSTR1 and SSTR5 stains with the underlying diseases (chronic hepatitis and cirrhosis) and gender was observed. Conclusions: This study demonstrated that the tumor cells in the tissue samples of the patients diagnosed with advanced-stage hepatocellular carcinoma expressed a high proportion of SSTR1 and SSTR5.